



CAPITAL RAISING PRESENTATION - JULY 2026

Bringing Quantum Computing to Australia

A strategic compute & capability partnership with **IonQ** (NYSE: IONQ)

Disclaimer

This presentation (**Presentation**), together with any information communicated by Archer Materials Limited (ACN 123 993 233) (the **Company** or **Archer**), in any presentation or discussion relating to this Presentation (collectively, **Information**) is confidential, and has been prepared by the Company on the condition that it is for the exclusive information and use of the recipient. The Information is proprietary to the Company and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company. Except as otherwise expressly stated in this Presentation, the Company has not authorised any person to give any information or make any representation which is not contained in this Presentation.

Not an Offer

The information contained in the Presentation is for information purposes only. The Presentation does not comprise a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law. The Presentation also does not constitute or form part of any invitation, offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to securities. In particular, this presentation may not be released to US wire services or distributed in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in the United States and elsewhere outside Australia may be restricted by law.

Not Investment Advice

The information contained in the Presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing the Presentation, the Company has not considered the objectives, financial position or needs of any particular recipient. The information contained in the Presentation is not a substitute for detailed investigation or analysis of any particular issue and does not purport to be all of the information that a person would need to make an assessment of the Company or its assets. Current and potential investors should seek independent advice before making any investment decisions in regard to the Company or its activities.

Summary Information

The Presentation does not purport to be all inclusive or to contain all information about the Company or any of the assets, current or future, of the Company. The Presentation contains summary information about the Company and its activities which is current as at the date of the Presentation. The information in the Presentation is of a general nature and does not purport to contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law.

Forward looking statements

The Presentation includes “forward looking statements” within the meaning of securities laws of applicable jurisdictions. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan”, “guidance” and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in such statement. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Given these uncertainties, recipients are cautioned to not place undue reliance on any forward looking statement. Subject to any continuing obligations under applicable law the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in this document to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based.

INVESTMENT HIGHLIGHTS

Capitalising on global quantum tailwinds



Australia's only listed quantum pure-play

ASX: AXE is the sole pure-play quantum technology exposure on the ASX.



A tier-one quantum partner

Three-year agreement with IonQ (NYSE: IONQ), the world's leading full-stack quantum platform company (~US\$21bn market cap).



Compute access secured

Cloud access to IonQ Forte-and Tempo-class systems, plus advisory to build sovereign capability in Australia.



Sovereign positioning

Strategy to become the natural Australian owner-operator of an IonQ system, backed by Archer's quantum R&D and IP.



Multiple revenue paths

Guaranteed cloud access, develop proprietary applications and IP, and monetise future local infrastructure.



A large, emerging market

Global quantum ~US\$130bn at maturity; Australian sovereign demand rising across defence, government and enterprise.

Australia's only listed pure-play quantum company

Archer Materials (ASX: AXE) is developing intellectual property across quantum computing, quantum software and sensing, with 40+ patents filed globally and partnerships with world-class research institutions and industry leaders.



Sovereign Quantum Compute

Bringing IonQ quantum computing to Australia



Quantum Software

Quantum machine learning & applications IP



Quantum Hardware

Carbon-based qubit & sensing technology

CORPORATE SNAPSHOT

254.8m

Shares on issue

\$0.31

Share price

\$79m

Market capitalisation

\$10.3m

Cash

Nil

Debt


~25%

Top 20 shareholders

Note 1: Capital structure and share price as at 23rd June 2026, Cash as at 31 March 2026

THE OPPORTUNITY

Quantum is moving from research to a multi-billion-dollar market



~\$129B

in annual revenue for quantum technology providers at maturity (2040)

Total market grows from ~\$2B today to \$27B by 2030 and \$129B by 2040, led by quantum computing.

Source: BCG analysis (total quantum technology market by segment, US\$B). Quantum computing assumes 20% technology-provider share of value created.

Why Australia needs quantum computing



National competitiveness

Quantum is a frontier technology expected to reshape productivity across finance, logistics, energy, materials and health.



Defence, intelligence & cyber

Five Eyes partners treat quantum as decisive for cryptography, secure communications and defence - driving sovereign demand.



World-class research, commercialisation gap

Two decades of Australian breakthroughs have yet to translate into local commercial-scale quantum capability.



Strategic national infrastructure

Sovereign quantum capability is increasingly viewed as critical national infrastructure, not a research curiosity.



AI-driven compute demand

Exponential growth in AI is straining classical compute and energy limits, accelerating the need for quantum.

THE PRIZE BY 2045

A\$6B

projected annual economic value to Australia from quantum technologies

~20,000

skilled Australian jobs expected across the quantum sector

Source: Australian Government National Quantum Strategy; CSIRO / 2024 State of Australian Quantum report.

Why Australia needs a quantum computer on Australian soil

OFFSHORE CLOUD ONLY - TODAY

- ✗ Data and workloads leave Australian jurisdiction
- ✗ Classified defence & government workloads effectively excluded
- ✗ Dependence on foreign providers and US export-control regimes
- ✗ Shared queues, latency and no guarantee of priority access
- ✗ Limited local skills, IP and supply-chain development

SOVEREIGN CAPABILITY - ON AUSTRALIAN SOIL

- ✓ Data and compute remain onshore and under Australian control
- ✓ Supports defence, intelligence and government-grade workloads
- ✓ Assured, prioritised access independent of foreign supply
- ✓ Builds local quantum IP, skills and supply chain
- ✓ Establishes strategic national computing infrastructure

THE RACE IS ON

Billions are being committed to sovereign quantum capability

A\$940M

Commonwealth + Queensland investment in PsiQuantum to build a utility-scale quantum computer in Brisbane

~A\$1B

Further earmarked for critical-technology and quantum companies via the National Reconstruction Fund

A\$146M+

Committed to National Quantum Strategy initiatives, including the Quantum Australia centre

38 / 26

Australian quantum firms and research organisations, backed by A\$179M+ private investment

THE COMPETITIVE FIELD

PsiQuantum (AU\$1B funding from QLD/Fed Gov) (Brisbane, photonic FTQC) · **Silicon Quantum Computing** · **Diraq** · **Quantum Brilliance** · **Q-CTRL** (US\$24M DARPA)

Most are private, unlisted and hardware-focused. **Archer is the only ASX-listed pure-play and is pursuing a commercial / infrastructure-platform route to sovereign capability.**

Sources: Australian & Queensland Government / DISR announcements (2024); 2024 State of Australian Quantum report; company analysis. Figures are indicative of public commitments.

SECTION

01

Sovereign Quantum Compute

Archer's strategy to bring IonQ quantum computing to Australia

ARCHER × IONQ

WHY IONQ

Partnering with the world's leading quantum platform company



~US\$21B

Market cap (NYSE: IONQ)

US\$3.3B

Cash & investments

US\$130M

FY25 revenue (+202% YoY)

US\$260–270M

FY26 revenue guidance (+104% YoY)

1,300+

Staff across 30+ countries

99.99%

Two-qubit gate fidelity (record)

- ✓ Full-stack quantum platform: computing, networking, sensing & security
- ✓ Trapped-ion architecture; datacentre-ready Forte and next-gen Tempo systems
- ✓ Technology roadmap toward 2 million qubits by 2030
- ✓ Customers and partners include including Amazon Web Services, Ansys, Google Cloud, Lockheed Martin, and AstraZeneca.
- ✓ In 2025, a joint project with AWS, NVIDIA and AstraZeneca demonstrated more than 20x improvement in computational performance compared to previous quantum implementations
- ✓ Selected for the US DARPA HARQ program in modular quantum computing

Sources: IonQ SEC filings and company announcements (FY2025 results, Q1 2026); figures as reported. Market capitalisation as at June 2026.

A phased path

PHASE 1

Development of client base and Archer applications

Initial Focus · now underway

- Access to cloud quantum computing, IonQ Forte/Tempo-class
- Customer acquisition and sales pipeline
- Government and defence engagement
- Build proprietary products & defensible IP
- IonQ + Archer Australian data-centre assessment

PHASE 2

Deploy sovereign infrastructure

Demand-driven: Subject to assessment

- Become the natural owner-operator of sovereign compute
- Driven by demand created in Phase 1
- Deploy a quantum system onshore
- Offer sovereign managed services
- Scale revenue from local compute

PHASE 3

Scale the platform

Long term

- Scale to a national quantum platform
- Expand into APAC opportunities
- Trusted operator of sovereign quantum infrastructure

Multiple revenue stream opportunities



Applications

Consulting, software and quantum-AI solutions



Services

Quantum access, subscriptions and managed services



Infrastructure

System deployment participation and ownership



Operations

Compute consumption, support and sovereign contracts

VISION Trusted operator of sovereign quantum infrastructure across Australia and APAC.



POSITIONING

Archer is the right partner for IonQ in Australia



Deep technical expertise

In-house quantum hardware, software and applications team.



Strategic IP

40+ patents filed globally across quantum and sensing, plus a growing quantum-algorithm IP base.



CSIRO QML work

Prototype QML fraud-detection models developed with CSIRO, benchmarked on simulated financial data.



Australian operating base

ASX-listed (ASX: AXE), Australian-incorporated; operations in Sydney and Adelaide (Lot Fourteen).



International Network

Network of international partners and collaborators.

PROOF POINTS

IonQ already deploys sovereign systems abroad



QuantumBasel - Switzerland

- First IonQ quantum computer deployed outside the US (Dec 2024)
- QuantumBasel now owns its Forte Enterprise system and a next-generation Tempo system
- Partnership valued at US\$60M+, extending IonQ's on-site presence through 2029



KISTI - South Korea

- IonQ Tempo to be integrated into KISTI-6, Korea's largest HPC cluster
- First on-site hybrid quantum–classical integration in the country
- Anchors South Korea's National Quantum Computing Centre of Excellence



A DEMONSTRATED TEMPLATE FOR AUSTRALIA

Switzerland and South Korea have demonstrated the model works. A local partner provides the data-centre and customer ecosystem while IonQ supplies, commissions and supports the quantum hardware - as a low cost, rapidly deployable sovereign solution.

Sources: IonQ / QuantumBasel and IonQ / KISTI announcements (2024–2026).

THE AGREEMENT

Key commercial terms

Secured, multi-year cloud compute and joint initiative to build sovereign capability and a customer base.

Overview	Archer has secured multi-year cloud access to IonQ's quantum computers plus a hands-on partnership to build local capability and a customer base
Compute Access	Cloud access to IonQ Forte-class (Tempo-class once available)
Consideration	US\$1.5M total - US\$250k on signing, then US\$250k every 6 months to month 30
Outcomes	Advisory, customer success & strategic collaboration, incl. Australian data-centre suitability assessment
Signed / term	Three-years term to mid - 2029
IP	Archer owns its inputs and results; may develop its own algorithms and IP

Source: Quantum Compute & Professional Services Agreement between Archer Materials Ltd and IonQ, Inc. (effective 18 June 2026).

SECTION

02

Quantum Software

Quantum machine learning and applications IP

SOFTWARE

Quantum machine learning, built for real-world value

- ✓ Partnered with CSIRO to develop quantum machine learning (QML) models for fraud detection
- ✓ Initial outputs: prototype QML models and performance benchmarks on simulated financial datasets
- ✓ The underlying QML framework is broadly applicable - healthcare, defence & aerospace, cybersecurity
- ✓ Builds defensible IP and the first steps of a customer application pipeline feeding the IonQ partnership

QML reinforces Archer's strategy to commercialise near-term quantum applications with global impact.



Prototype QML fraud-detection models on simulated financial data

SECTION

03

Quantum Hardware

Carbon-based qubit and sensing technology

HARDWARE

How Archer solves the barriers to quantum hardware

Quantum computers process information beyond the limits of classical machines - but face significant manufacturing barriers. Archer is addressing them with carbon-based technology designed to operate in real-world environments.



Cooling

Reducing the extreme cooling required by conventional qubits




Stability

Improving qubit stability and control for reliable operation



Integration

Integrating with today's semiconductor fabrication and chips



Significant advantages of Archer's quantum chip



Designed for scalability

Built with materials and processes that can scale using today's semiconductor fabrication and integrate with today's chips.



Improved control

Improved control capability and stability - a key enabler for building a utility-scale computing system.



Versatile foundation

Carbon-based materials provide a foundation for sensing and low-power electronics, in addition to computing.



Commercial focus

A roadmap aimed at licensing and industry partnerships rather than building full quantum machines in-house.

Lab-on-a-chip biosensing

- ✓ Carbon-based biochip targeting point-of-care blood testing (initial focus: blood potassium)
- ✓ Lab demonstrator / alpha prototype delivered; beta prototype targeted for trials
- ✓ Clinical-trial pathway and North American regulatory engagement underway
- ✓ Next-generation biosensor in development from Archer's R&D pipeline



PARTNERSHIPS

A global network advancing Archer's technology



SWITZERLAND

EPFL

Quantum chip components



BELGIUM

imec

Biosensor manufacturability & integration



UNITED STATES

IonQ

Full stack quantum platform & merchant



UNITED KINGDOM

Paragraf

Potassium sensing accuracy & reliability



CANADA

HyliDx

Biochip cartridge & CKD regulatory pathway



AUSTRALIA

CSIRO

Quantum machine learning



AUSTRALIA

Emergence
Quantum

Quantum sensing integration

Archer's quantum business growth pipeline

ARCHER'S PROPRIETARY IP

- Advanced qubit chips & sensors
- Manufacturing readiness



STRATEGIC PARTNERSHIP

- Quantum computing platform
- Customer use-case development & software deployment

MARKET EXPANSION

- QML applications
- Hardware partnerships in comms & AI
- PQC advisory & solution delivery

SOVEREIGN QUANTUM CAPABILITY

- Quantum computing capability on Australian soil
- Build a broader quantum ecosystem
- Long-term recurring revenue via hardware, software & licensing

INVESTMENT CASE

Investment Summary

INVESTMENT HIGHLIGHTS



Sovereign quantum first-mover

Australia's first sovereign quantum platform.



Australia's only listed pure-play

Only pure-play quantum exposure on the ASX.



Tier-one IonQ partnership

Multi-year agreement with quantum leader IonQ.



Low-capex, high-margin model

In-house R&D, scaled via foundry & partners.



Expanding, defensible IP

40+ patents filed globally, plus growing IP.



Deep technical leadership

Deep-tech team with global scientific advisors.

KEY CATALYSTS

1

Working qubit demo — Q3 CY2026

On track to demonstrate a working 12CQ qubit in CY2026.

2

Wafer-scale manufacturing

Full-wafer graphene runs underway on foundry-grade lines.

3

QML development pathway

Fraud-detection model validated on live quantum hardware.

4

IonQ stage 1

Customer engagement underway along with data centre search

5

IonQ stage 2

Development towards sovereign quantum compute capability

6

Partnership & M&A Opportunities

Actively seeking to expand global quantum network

SECTION

04

Capital Raising

Archer has received firm commitments to raise A\$7.0m via a two-tranche Placement.

ARCHER

THE OFFER

Offer summary & use of funds

Placement

- A two-tranche Placement to sophisticated and professional investors of \$7.0m, comprising of:
 - Tranche 1 Placement to raise approximately \$6.86 million (before costs) through the issuance of approximately 25.4 million New Shares utilising the Company's available placement capacity under ASX Listing Rule 7.1 ("Tranche 1 Placement"); and
 - Tranche 2 Placement to Directors and Management of Archer to raise \$0.14 million (before costs) through the issuance of 0.52 million New Shares, subject to shareholder approval for Director participation at an Extraordinary General Meeting ("EGM") to be held around mid-August 2026 ("Tranche 2 Placement" or "Director Placement").

Offer price

- Placement Offer Price of A\$0.27 per New Share represents a:
 - 12.9% discount to the last close of A\$0.310 as at Tuesday, 30 June 2026 ; and
 - 13.6% discount to the 5-day volume weighted average share price of \$0.312 per share.

Share Purchase Plan

- Archer will offer Eligible Shareholders the opportunity to participate in a Security Purchase Plan ("SPP") and apply up to \$30,000 of New Shares to raise up to A\$3.0 million, and will be offered at A\$0.27 per New Share, being the price paid under the Placement;
- Archer reserves the right to increase the size of the SPP or to scale back applications in its absolute discretion
- Further details in relation to the SPP including the timetable will be provided to eligible shareholders in an SPP booklet expected to be released following the Placement

Attaching Options

- Participants in the Placement and SPP will receive the opportunity to subscribe for one (1) free unquoted attaching option for every one (1) New Share allocated in the Offer, expiring on 30 June 2029 with an exercise price of A\$0.35 per Attaching Option ("Attaching Options")
- Issuance of Attaching Options pursuant to the Placement will be conditional on shareholder approval at the EGM to be held around mid-August 2026

Use of Funds

- Use of funds to support Quantum programs (IonQ client development & project development, QML development & qubit development), Biochip Development & working capital

Ranking

- New Shares rank pari passu with existing shares on issue

Lead manager

- Bell Potter Securities Limited (Bell Potter) acted as Lead Manager and Bookrunner to the Placement

THE OFFER

Offer timetable

Indicative Capital Raising Timetable¹

Date

Trading Halt and Bookbuild Opens	Wednesday, 1 July 2026
Bookbuild closes	4:00pm (Sydney Time) Wednesday, 1 July 2026
SPP record date	7:00pm (AEST) Thursday, 2 July 2026
Announcement of Capital Raising and trading halt is lifted	Friday, 3 July 2026
Settlement of New Shares issued under the Tranche 1 Placement	Wednesday, 8 July 2026
Allotment of New Shares issued under the Tranche 1 Placement	Thursday, 9 July 2026
SPP Opens	Friday, 10 July 2026
SPP Closes	Monday, 3 August 2026
EGM to approve issue of New Shares under Tranche 2 of the Placement and Attaching Options	Expected mid-August 2026
Settlement of New Shares issued under the Tranche 2 Placement and Attaching Options	Expected mid-August 2026
Allotment of New Shares issued under the Tranche 2 Placement and Attaching Options	Expected mid-August 2026

1. Indicative only and the Lead Manager and the Company reserve the right to close the Book early without notice

THE OFFER

Foreign Selling Restrictions

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the “SFO”). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to “professional investors” (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”).

The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Singapore

This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore.

Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the “SFA”) or another exemption under the SFA.

This document has been given to you on the basis that you are an “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.

Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

Risks

The following describes some of the external factors and business risks that could have a material impact on the Company's ability to deliver its strategy:

Access to Funding

The Company does not receive any income from its operating business and is reliant on capital raisings, Commonwealth Government research and development tax incentives, and the sale of non-core assets to fund its future operations. Therefore, the Company's ability to continue developing its technology is contingent upon its ability to secure timely access to additional funding as required.

Key Agreements

Development and potential commercialisation of the 12CQ quantum technology intellectual property and associated patents and patent applications are dependent on the Licence Agreement with the University of Sydney remaining in-place. Termination of the Licence Agreement would mean that Archer would be unable to access the intellectual property required to commercialise the associated quantum technology.

Development and potential commercialisation of the transaction with IonQ depend on the agreement with IonQ remaining in force. Termination of this agreement would mean that Archer would be unable to access or purchase an IonQ quantum computer.

Intellectual Property

Commercially exploiting and legally protecting the intellectual property underlying the Company's technology, including its graphene-based lab-on-a-chip biochip technology development, is dependent on the Company progressing its associated patent applications.

The protection of intellectual property, including patents and patent applications, has the potential for third-party claims against the Company's owned or licensed intellectual property. There is a risk that all reasonable efforts by the Company to protect proprietary rights may not be sufficient or effective, including risks that intellectual property may not have adequate patent or copyright protection for certain innovations, that the scope of available protections is insufficient, or that an issued patent may be deemed invalid or unenforceable in certain jurisdictions.

Potential mergers, acquisitions and divestments

As part of its business strategy, the Company may make acquisitions or divestments of, or significant investments in, companies, products, technologies or technology projects. Any such future transactions would be subject to the risks commonly encountered in making acquisitions or divestments of companies, products, technologies, or technology projects.

Cyber Security Risk

Breaches of cyber security is a growing global risk as the volume and sophistication of threats have increased. Risks include unauthorised access to data and information, malicious attacks resulting in outages and disruptions to operations and ransom demands with financial consequences to the Company.

Risks

Key Personnel

The Company's technology is unique, with very few people available globally with the required knowledge, skills, relationships, and experience to develop the technologies towards future possible commercialisation. The Company's projects may be delayed or materially adversely affected if key personnel are not available to work.

Potential commercial viability of products

The 12CQ, sovereign data compute and biochip projects are in the research and development phase. Company staff and external consultants are in laboratories conducting experiments to determine if the materials underlying the technologies can perform as predicted. There is no guarantee that these experiments will be successful.

The Company has not yet commercialised any products and as yet has no revenues. The Company's ability to commercialise the intellectual property and sell products to customers may be affected by many factors, including the commercial viability of, and potential delays in, the delivery of products and technology and the ability to find customers for the Company's products. There is no certainty that the Company will be able to make and sell commercially viable products.

Regulatory and Compliance Risk

For technologies in the medical and quantum fields, navigating complex and evolving regulatory environments is critical. Medical technologies, in particular, must meet strict safety, performance, and ethical standards before they can be sold or even tested in human trials. This includes approvals from regulatory bodies such as the Therapeutic Goods Administration (TGA) in Australia, the FDA in the United States, and relevant European agencies. Non-compliance or delays in obtaining approvals can stall product development and increase costs.

In the quantum sector, while regulation is less mature, increasing global attention on data security, cryptography, and dual-use technology may lead to new compliance challenges. Failure to meet these emerging regulatory obligations—or to anticipate them in the design and application of the technology—could limit market access or expose the company to fines and reputational damage.

Market Adoption Risk

Even if the Company successfully develops operational quantum or medical technologies, market acceptance is not guaranteed. Quantum computing is still an emerging field, and its applications are not yet fully integrated into mainstream commercial operations. Similarly, new medical diagnostic tools often face resistance from clinicians, health systems, or patients due to unfamiliarity, perceived complexity, or insufficient clinical validation.

If customers are hesitant to adopt new technologies, or if the Company fails to demonstrate clear benefits over incumbent solutions, the commercial potential of the product may be undermined. This risk is amplified in highly conservative or cost-sensitive sectors like healthcare, where new tools must not only work but also integrate seamlessly into existing systems and workflows. Commercial partners The Company's growth strategy may be impacted if it is unable to find suitable commercialisation partners. The Company's due diligence processes and commercial negotiations may not be successful and a commercial partnership may not eventuate or if finalised may not perform to the level expected. Changes in economic conditions General economic conditions, movements in financial markets, interest and inflation rates and currency exchange rates may have an adverse effect on the Company's business and activities, as well as on its ability to fund those activities.

Risks

Commercial partners

The Company's growth strategy may be impacted if it is unable to find suitable commercialisation partners. The Company's due diligence processes and commercial negotiations may not be successful, and a commercial partnership may not eventuate or, if finalised, may not perform to the level expected. Changes in economic conditions, movements in financial markets, interest and inflation rates and currency exchange rates may have an adverse effect on the Company's business and activities, as well as on its ability to fund those activities.

Changes in economic conditions

General economic conditions, movements in financial markets, interest and inflation rates and currency exchange rates may have an adverse effect on the Company's business and activities, as well as on its ability to fund those activities.



Thank you

Building Australia's sovereign quantum computing capability

Archer Materials Limited

ASX: AXE · archerx.com.au

Simon Ruffell · hello@archerx.com.au

+61 466 785 114

This presentation has been authorised for release by the Board of Archer Materials Limited

Disclaimer: This presentation is for information purposes only and does not constitute financial product advice or an offer to subscribe for securities. It contains forward-looking statements and references to third-party information; actual outcomes may differ. Recipients should seek their own advice.